CN109700720B - 一种婴儿护理膏及其制备方法 - Google Patents
一种婴儿护理膏及其制备方法 Download PDFInfo
- Publication number
- CN109700720B CN109700720B CN201910135866.6A CN201910135866A CN109700720B CN 109700720 B CN109700720 B CN 109700720B CN 201910135866 A CN201910135866 A CN 201910135866A CN 109700720 B CN109700720 B CN 109700720B
- Authority
- CN
- China
- Prior art keywords
- extract
- care cream
- infant care
- stearate
- menthol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006071 cream Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 30
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 20
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 15
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 14
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940041616 menthol Drugs 0.000 claims abstract description 14
- 229920001577 copolymer Polymers 0.000 claims abstract description 12
- 229940099259 vaseline Drugs 0.000 claims abstract description 12
- 229940075999 phytosterol ester Drugs 0.000 claims abstract description 11
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 10
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 10
- 229960000458 allantoin Drugs 0.000 claims abstract description 10
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 10
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract description 10
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 10
- -1 polydimethylsiloxane Polymers 0.000 claims abstract description 10
- 239000000230 xanthan gum Substances 0.000 claims abstract description 10
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 10
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 10
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 9
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 9
- 229940116229 borneol Drugs 0.000 claims abstract description 9
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 9
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940075529 glyceryl stearate Drugs 0.000 claims abstract description 9
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 9
- 229940039697 alkanna tinctoria root extract Drugs 0.000 claims abstract description 7
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 claims abstract description 5
- 102000008186 Collagen Human genes 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 12
- 229920001436 collagen Polymers 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 241000736199 Paeonia Species 0.000 claims description 9
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 9
- 229910021641 deionized water Inorganic materials 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 229920000136 polysorbate Polymers 0.000 claims description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 7
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 7
- 229960005323 phenoxyethanol Drugs 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 240000007311 Commiphora myrrha Species 0.000 claims description 4
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 4
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 4
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 4
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 4
- 239000013065 commercial product Substances 0.000 claims description 4
- 241000245165 Rhododendron ponticum Species 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 abstract description 5
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 abstract description 5
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 abstract description 4
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 abstract description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract description 4
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 abstract description 4
- 229940036350 bisabolol Drugs 0.000 abstract description 4
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 abstract description 4
- 230000035876 healing Effects 0.000 abstract description 3
- 230000005808 skin problem Effects 0.000 abstract description 3
- 201000004681 Psoriasis Diseases 0.000 abstract description 2
- 229960003966 nicotinamide Drugs 0.000 abstract description 2
- 235000005152 nicotinamide Nutrition 0.000 abstract description 2
- 239000011570 nicotinamide Substances 0.000 abstract description 2
- 230000036555 skin type Effects 0.000 abstract description 2
- 229960004063 propylene glycol Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 25
- 206010014198 Eczema infantile Diseases 0.000 description 16
- 201000008937 atopic dermatitis Diseases 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 8
- 239000002674 ointment Substances 0.000 description 7
- 230000001804 emulsifying effect Effects 0.000 description 6
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 5
- 229940104261 taurate Drugs 0.000 description 5
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 229940084750 sophora flavescens root extract Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000246044 Sophora flavescens Species 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 1
- 239000004229 Alkannin Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- 235000019232 alkannin Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
本发明属于儿童护理技术领域，提供了一种婴儿护理膏，包括丙二醇、汉生胶、尿囊素、司盘60、吐温60、脂肪醇、甘油硬脂酸酯/PFG100‑硬脂酸酯、植物甾醇酯、医药凡士林、维生素E醋酸酯、没红药醇、聚二甲基硅氧烷、丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物、紫草根提取物、薄荷脑、冰片、烟酰胺等。该婴儿护理膏能够有效快速地治疗婴幼儿奶癣，而且能够用于多种肤质，不会在使用时引发新的皮肤问题，通过添加植物甾醇提升了薄荷脑的稳定性，通过添加氮酮降低了治愈后的复发率。
Description
技术领域
本发明属于儿童护理技术领域，具体涉及一种婴幼儿护理膏。
背景技术
皮肤是婴儿全身最大的器官，它可以保护婴儿免受外界各种刺激，调节体温，作为保护层防止有害物的入侵。由于婴儿真皮弹性纤维少，发育尚未成熟，加上婴儿汗腺未发育完全，汗液排出能力较差，抗感染能力较差等诸多原因，皮肤很容易出现皮炎症状，给患儿造成痛苦，也增加家长的经济负担。
奶癣是婴幼儿期最常见的皮肤病之一，皮疹多见于两颊、前额及头皮，以后可蔓延至颈、肩、臂，甚至扩大到腹、臀、四肢及全身。皮疹形态不一，自红斑、丘疹、疱疹至渗液、糜烂、结痂和脱屑，以瘙痒及反复发作为临床特点。常见于1个月至1岁以内哺乳婴儿，尤以百日之内的婴儿更为多见。奶癣又名胎疮。西医称为婴儿湿疹，病因不明，患儿常有家族过敏史，多见于人工哺育的婴儿。奶癣已成为发达国家及发展中国家儿童最常见的皮肤问题，其发生率在过去30年增加了2-3倍，影响了15％-20％的儿童的生活质量。
不少家长担心药物的安全性，拒绝使用药物，例如，中国专利申请2015102150826中公开了一种婴儿湿疹膏，其主要成分按重量份数计为羊毛酯100份、苯海拉明22-25份、乳酸钠14-19份、薄荷脑2-5份、甘草次酸0.5-2份，此配方中苯海拉明为抗组胺药，具有抗组织胺H1受体的作用，对中枢神经有较强的抑制作用，并且容易产生副作用，所以一般不被患儿家长接受。而自行在家外敷粉质剂，容易加重病情，甚至波及全身。
现代治疗婴儿湿疹往往采用西药，而西药往往含有激素类物质，副作用大且治标不治本，停药又复发，只起到一时的缓解作用。中国专利公布CN104784314A公开了一种治疗奶癣的中药膏，由以下重量计的原料药物：黄芩15-30g、黄柏15-30g、黄连15-30g和枯矾3-5g，共研细末，加凡士林配成软膏制成。这种采用单纯清热解毒的中药制剂，虽然副作用变小，但不能根治，会出现停药又复发的现象。
因此目前需要一种中西药结合、治疗效果好、显效快、副作用小，且治疗后不易反复的奶癣治疗膏。
发明内容
本发明提供了一种适用于婴幼儿的湿疹治疗膏，能够有效快速地治疗婴幼儿奶癣，而且能够用于多种肤质，不会在使用时引发新的皮肤问题。
本发明提供了一种婴儿护理膏，按重量百分含量计，包括以下组分：丙二醇0.5-5％、汉生胶0.1-0.5％、尿囊素0.2-1％、司盘60 1-2％、吐温60 1-3％、脂肪醇1-5％、甘油硬脂酸酯/PFG100-硬脂酸酯0.2-1.5％、植物甾醇酯0.5-5％、医药凡士林5-15％、维生素E醋酸酯0.1-1.2％、没红药醇0.1-0.5％、聚二甲基硅氧烷0.2-1.2％、丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物0.1-1％、紫草根提取物2-10％、薄荷脑0.1-0.5％、冰片0.1-0.5％、烟酰胺0.5-5％、牡丹皮提取物0.1-0.5％、苦参根提取物0.1-1.5％、芍药提取物0.5-5％、苯氧乙醇0.1-1％和去离子水余量。
甘油硬脂酸酯/PFG100-硬脂酸酯中甘油硬脂酸酯和PFG100-硬脂酸酯的质量比为1:1。
丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物中丙烯酰二甲基牛磺酸铵和乙烯基吡咯烷酮共聚物的质量比为1:1。
所述的婴儿护理膏，其特征在于：按重量百分含量计，包括以下组分：丙二醇1-2％、汉生胶0.1-0.2％、尿囊素0.2-0.3％、司盘60 1-1.6％、吐温60 1.2-1.8％、脂肪醇1-3％、甘油硬脂酸酯/PFG100-硬脂酸酯0.5-1％、植物甾醇酯1-3％、医药凡士林8-10％、维生素E醋酸酯0.3-1％、没红药醇0.1-0.2％、聚二甲基硅氧烷0.5-1.0％、丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物0.3-0.5％、紫草根提取物5-8％、薄荷脑0.2-0.3％、冰片0.2-0.3％、烟酰胺1-3％、牡丹皮提取物0.2-0.3％、苦参根提取物0.1-1％、芍药提取物1-3％、苯氧乙醇0.4-0.6％和去离子水余量。
在一些优选的方案中，所述婴儿护理膏中还含有氮酮。
在一些优选的方案中，所述婴儿护理膏中含有重量百分含量1-8％的氮酮。
在一些优选的实施方案中，所述婴儿护理膏中还含有质量比为1:1的胶原蛋白和明胶。
在一些优选的实施方案中，所述婴儿护理膏中胶原蛋白的重量百分含量为0.5-2.5％。
所述紫草根提取物为市售产品。
所述牡丹皮提取物为市售产品。
所述苦参根提取物市售产品。
所述芍药提取物市售产品。
本发明提供了一种婴儿护理膏的制备方法：
(1)首先将丙二醇、汉生胶、丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物、尿囊素和去离子水加入到水相锅中，搅拌使分散均匀，并加热至85-90℃，保温搅拌20-30min，得到混合物A，备用；
(2)将司盘(S60)、吐温(T60)、脂肪醇、甘油硬脂酸酯/PFG100-硬脂酸酯、植物甾醇酯、医药凡士林和聚二甲基硅氧烷加入油相锅中，搅拌使分散均匀，升温至85-90℃，保温搅拌20-30min，得到混合物B，备用；
(3)将步骤(1)中得到的混合物A抽入真空乳化锅中，并开启中速搅拌，待混合物A抽完后，继续将步骤(2)中得到的混合物B抽入乳化锅中，待混合物B抽完后，开启高速搅拌进行均质乳化15-20min，均质后保温搅拌10-15min后，抽真空搅拌降温，得到混合物C；
(4)待步骤(3)中得到的混合物C降温至60℃时，将维生素E醋酸酯、没红药醇和紫草根提取物加入乳化锅中，后开启搅拌至分散均匀，得到混合物D：
(5)继续降温，待步骤(4)中得到的混合物D降温至45℃时，将烟酰胺、牡丹皮提取物、苦参根提取物和芍药提取物加入乳化锅中，开启搅拌至完全分散均匀，得到混合物E；
(6)继续降温，待步骤(5)中得到的混合物E降温至38℃时，将苯氧乙醇、薄荷脑、冰片加入乳化锅中，搅拌至完全分散均匀，得到混合物F；
(7)取样检测步骤(6)中得到的混合物F，检测合格后，将混合物F过200目滤网，过滤出料，包装，即得成品。
本发明还提供了一种婴儿护理膏的制备方法：
(1)首先将丙二醇、汉生胶、丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物、尿囊素、医药凡士林、胶原蛋白和去离子水加入到水相锅中，搅拌使分散均匀，并加热至85-90℃，保温搅拌20-30min，得到混合物A；
(2)将司盘60、吐温60、脂肪醇、甘油硬脂酸酯/PFG100-硬脂酸酯、植物甾醇酯、明胶和聚二甲基硅氧烷加入油相锅中，搅拌使分散均匀，升温至85-90℃，保温搅拌20-30min，得到混合物B；
(3)将步骤(1)中得到的混合物A步骤(2)得到的混合物B搅拌混合10-15min；得到混合物C；
(4)待步骤(3)中得到的混合物C降温至40℃时，加入余量物质，搅拌混匀，过筛出料，即得成品。
所述步骤(4)中混匀后的物料过200目筛。
与现有技术相比，本发明的有益效果为：
(1)本发明通过在本发明配方的基础上，使用植物甾醇酯增强了薄荷脑的稳定性，减少了制备和存储过程中薄荷脑的损失。
(2)本发明通过在婴儿膏中添加司盘60和吐温60，增强了含有较多医用凡士林的膏剂对脂溢性皮肤的适用性，拓宽了膏剂的使用范围。
(3)本发明通过添加氮酮，降低了奶癣治愈之后的复发率，提升了婴儿后期对湿疹的抵抗力。
(4)本发明通过添加质量比为1:1的胶原蛋白和明胶，进一步降低了奶癣治愈后的复发率。
具体实施方式
除非另外定义，本文中使用的所有技术和科学术语具有与本发明所属技术领域的普通技术人员通常理解的相同意义。实施例中未注明具体技术或条件者，按照本领域内的常规技术手段进行。
说明：本申请表格中的“-”表示未对该指标进行检测。
实施例1婴儿护理膏
按重量百分含量计，包括以下组分：丙二醇0.5％、汉生胶0.5％、尿囊素0.2％、司盘60 2％、吐温60 1％、脂肪醇5％、甘油硬脂酸酯/PFG100-硬脂酸酯0.2％、植物甾醇酯5％、医药凡士林5％、维生素E醋酸酯1.2％、没红药醇0.1％、聚二甲基硅氧烷1.2％、丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物0.1％、紫草根提取物10％、薄荷脑0.1％、冰片0.5％、烟酰胺0.5％、牡丹皮提取物0.5％、苦参根提取物0.1％、芍药提取物5％、苯氧乙醇0.1％和去离子水余量。
实施例2婴儿护理膏
按重量百分含量计，包括以下组分：丙二醇5％、汉生胶0.1％、尿囊素1％、司盘601％、吐温60 3％、脂肪醇1％、甘油硬脂酸酯/PFG100-硬脂酸酯1.5％、植物甾醇酯0.5％、医药凡士林15％、维生素E醋酸酯0.1％、没红药醇0.5％、聚二甲基硅氧烷0.2％、丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物1％、紫草根提取物2％、薄荷脑0.5％、冰片0.1％、烟酰胺5％、牡丹皮提取物0.1％、苦参根提取物1.5％、芍药提取物0.5％、苯氧乙醇1％和去离子水余量。
实施例3婴儿护理膏
按重量百分含量计，包括以下组分：丙二醇1.5％、汉生胶0.2％、尿囊素0.5％、司盘60 1.2％、吐温60 2％、脂肪醇3％、甘油硬脂酸酯/PFG100-硬脂酸酯1.1％、植物甾醇酯2％、医药凡士林8％、维生素E醋酸酯1.1％、没红药醇0.3％、聚二甲基硅氧烷1.1％、丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物0.5％、紫草根提取物8％、薄荷脑0.2％、冰片0.3％、烟酰胺0.9％、牡丹皮提取物0.4％、苦参根提取物1.1％、芍药提取物3％、苯氧乙醇0.9％和去离子水余量。
实施例4婴儿护理膏
和实施例1的区别仅在于，在实施例1的基础上添加了8％重量份的氮酮。
实施例5婴儿护理膏
和实施例2的区别仅在于，在实施例2的基础上添加了1％重量份的氮酮。
实施例6婴儿护理膏
和实施例3的区别仅在于，在实施例3的基础上添加了5％重量份的氮酮。
实施例7婴儿护理膏
和实施例6的区别仅在于，在实施例6的基础上添加了胶原蛋白和明胶(m:m＝1:1),其中，胶原蛋白为2％重量份。
实施例8婴儿护理膏
和实施例2的区别仅在于，在实施例2的基础上添加了添加了胶原蛋白和明胶(m:m＝1:1),其中，胶原蛋白为0.5％重量份。
对比例1婴儿护理膏
和实施例3的区别在于省略了植物甾醇的添加。
对比例2婴儿护理膏
和实施例3的区别在于省略了司盘60和吐温60的添加。
实验方法：临床随机选取患有湿疹的婴幼儿病患(低于2岁)100例，其中，男孩30例，女孩20例，病患年龄均在1月-2岁之间，年龄最小患儿32天、最大患儿23个月。其中，干燥型婴儿湿疹50例，脂溢性婴儿湿疹50例。
疗效标准：以患儿病变完全消失、皮肤恢复正常为治愈；以患儿病变减轻、患病程度降低为有效；若病变无变化或程度加重则视为无效。同时记录发生副作用的病例。
表1中的实验数据表明使用本申请的制备方法，能获得具有良好治疗效果的婴儿护理膏。实施例3和对比例1的实验数据说明，植物甾醇的添加，能有效提升薄荷脑的稳定性。实施例3和对比例1的实验数据说明，司盘60和吐温60的添加，改善了婴儿护理膏对脂溢性婴儿湿疹的适用效果。实施例3和实施例6的实验结果表明氮酮的添加能够降低治愈后的复发率。实施例2和实施例8的实验结果表明，明胶和胶原蛋白的添加，能够降低后期复发率。
表1
Claims (4)
1.一种婴儿护理膏，其特征在于，按重量百分含量计，包括以下组分：丙二醇0.5-5％、汉生胶0.1-0.5％、尿囊素0.2-1％、司盘60 1-2％、吐温60 1-3％、脂肪醇1-5％、甘油硬脂酸酯/PFG100-硬脂酸酯0.2-1.5％、植物甾醇酯0.5-5％、医药凡士林5-15％、维生素E醋酸酯0.1-1.2％、没红药醇0.1-0.5％、聚二甲基硅氧烷0.2-1.2％、丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物0.1-1％、紫草根提取物2-10％、薄荷脑0.1-0.5％、冰片0.1-0.5％、烟酰胺0.5-5％、牡丹皮提取物0.1-0.5％、苦参根提取物0.1-1.5％、芍药提取物0.5-5％、苯氧乙醇0.1-1％、氮酮1-8％、质量比为1:1的胶原蛋白和明胶、去离子水余量；所述胶原蛋白的重量百分含量为0.5-2.5％。
2.根据权利要求1所述的婴儿护理膏，其特征在于，按重量百分含量计，包括以下组分：丙二醇1-2％、汉生胶0.1-0.2％、尿囊素0.2-0.3％、司盘60 1-1.6％、吐温60 1.2-1.8％、脂肪醇1-3％、甘油硬脂酸酯/PFG100-硬脂酸酯0.5-1％、植物甾醇酯1-3％、医药凡士林8-10％、维生素E醋酸酯0.3-1％、没红药醇0.1-0.2％、聚二甲基硅氧烷0.5-1.0％、丙烯酰二甲基牛磺酸铵/乙烯基吡咯烷酮共聚物0.3-0.5％、紫草根提取物5-8％、薄荷脑0.2-0.3％、冰片0.2-0.3％、烟酰胺1-3％、牡丹皮提取物0.2-0.3％、苦参根提取物0.1-1％、芍药提取物1-3％、苯氧乙醇0.4-0.6％、氮酮1-8％、质量比为1:1的胶原蛋白和明胶、去离子水余量；所述胶原蛋白的重量百分含量为0.5-2.5％。
3.根据权利要求1所述的婴儿护理膏，其特征在于：所述紫草根提取物为市售产品、所述牡丹皮提取物为市售产品。
4.根据权利要求1所述的婴儿护理膏，其特征在于：所述苦参根提取物为 市售产品、所述芍药提取物为 市售产品。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810275866.1A CN108324612A (zh) | 2018-03-30 | 2018-03-30 | 一种婴儿护理膏及其制作方法 |
| CN2018102758661 | 2018-03-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109700720A CN109700720A (zh) | 2019-05-03 |
| CN109700720B true CN109700720B (zh) | 2020-02-14 |
Family
ID=62931779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810275866.1A Pending CN108324612A (zh) | 2018-03-30 | 2018-03-30 | 一种婴儿护理膏及其制作方法 |
| CN201910135866.6A Active CN109700720B (zh) | 2018-03-30 | 2019-02-25 | 一种婴儿护理膏及其制备方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810275866.1A Pending CN108324612A (zh) | 2018-03-30 | 2018-03-30 | 一种婴儿护理膏及其制作方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN108324612A (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481370A (zh) * | 2018-12-29 | 2019-03-19 | 广东添乐化妆品有限公司 | 一种舒缓抗过敏抗刺激护肤组合物及其制备方法和应用 |
| CN110755323B (zh) * | 2019-11-26 | 2021-02-19 | 苏州东方之宝生物药业有限公司 | 一种紫草护理膏及其制备方法 |
| CN114259513A (zh) * | 2021-12-29 | 2022-04-01 | 彭氏(惠州)实业发展有限公司 | 护理膏及其制备方法 |
| CN115569093B (zh) * | 2022-09-09 | 2023-10-13 | 安徽亿人安股份有限公司 | 一种具有抗菌作用的婴儿祛湿护肤膏及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003292451A (ja) * | 2002-04-01 | 2003-10-15 | Noevir Co Ltd | 皮膚外用剤 |
-
2018
- 2018-03-30 CN CN201810275866.1A patent/CN108324612A/zh active Pending
-
2019
- 2019-02-25 CN CN201910135866.6A patent/CN109700720B/zh active Active
Non-Patent Citations (2)
| Title |
|---|
| 利贝婴儿 护理膏;广州盛欣化妆品有限公司;《国产非特殊用途化妆品备案》;20170824;成分 * |
| 利贝婴儿 护理膏;广州盛欣化妆品有限公司;《国产非特殊用途化妆品备案》;20171117;成分 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108324612A (zh) | 2018-07-27 |
| CN109700720A (zh) | 2019-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109700720B (zh) | 一种婴儿护理膏及其制备方法 | |
| KR20120084723A (ko) | 소염, 부기제거, 진통에 사용되는 중국 생약 조성물, 그 제조 방법 및 용도 | |
| WO2018137319A1 (zh) | 大叶清香桂的应用，治疗皮肤病的中药膏剂、制备方法及其应用 | |
| CN104873446A (zh) | 一种含肉桂油的牙膏 | |
| CN116603012A (zh) | 一种中药凝胶及其制备方法和应用 | |
| CN106237030A (zh) | 一种治疗婴幼儿湿疹的中药组合物及其制备方法 | |
| CN109394768B (zh) | 一种治疗湿疹的药物及其制备方法 | |
| CN106728069B (zh) | 一种治疗烫烧伤的祛腐生肌膏 | |
| KR100860350B1 (ko) | 생약추출물을 함유하는 모발생장촉진용 화장료 조성물 | |
| CN110025705A (zh) | 一种治疗特应性皮炎的中药组合物及其制备方法和应用 | |
| CN110075199A (zh) | 一种治疗银屑病的中药组合物及其制备方法和应用 | |
| CN115414427B (zh) | 治疗慢性皮肤瘙痒症的中药组合物及其制备方法、用途 | |
| CN107929346A (zh) | 治疗湿疹的中药组合物及其制备方法 | |
| CN103690902B (zh) | 用于预防鼻咽癌放化疗放射副反应的中药制剂 | |
| CN102784216A (zh) | 一种治疗脱发的藏药 | |
| CN113318072A (zh) | 一种用于治疗带状疱疹的复方雄黄软膏及其制备方法 | |
| JP2004352680A (ja) | アレルギー性疾患治療用組成物 | |
| CN114259513A (zh) | 护理膏及其制备方法 | |
| CN113440560A (zh) | 一种治疗小儿慢性湿疹的药物组合物 | |
| CN104857185A (zh) | 一种预防麻醉后寒战的中药及制备方法 | |
| CN114632127A (zh) | 一种治疗小儿黄疸的中药组合物、制剂及其制备方法和应用 | |
| CN1090493C (zh) | 治疗肺结核的麝蜂椿枣根皮制剂及其生产方法 | |
| CN105287951A (zh) | 一种能淡化色斑的组合物及其制备方法 | |
| CN105194237A (zh) | 一种治疗淋巴癌的组合物及其制备方法 | |
| CN109432322A (zh) | 一种预防和治疗口腔溃疡的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240403 Address after: Room 402, 4th Floor, No. 43 Wenhai West Road, Hongxing Community, Ronggui Street, Shunde District, Foshan City, Guangdong Province, 528305 Patentee after: Foshan Libeiai Biotechnology Co.,Ltd. Country or region after: China Address before: No.19, south of Longhe East Road, Longgui Yongxing Village, Taihe Town, Baiyun District, Guangzhou City, Guangdong Province, 510540 Patentee before: GUANGZHOU SHENGXIN COSMETIC Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |